Lonza: Biologic APIs boosted H1 revs and CAR-T deal will help sustain growth in H2
Lonza has increased its 2016 earnings guidance after strong H1 growth of its biologic APIs business.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs